褪黑素在甲状腺乳头状癌转移中的作用评估

范立; 熊园平; 刘海涛; 闵翔; 汤燕琴; 张志远

doi:10.13201/j.issn.1001-1781.2019.11.013

褪黑素在甲状腺乳头状癌转移中的作用评估

- 南昌大学第一附属医院耳鼻咽喉头颈外科(南昌, 330006)
基金项目:
江西省教育厅科学技术研究项目(No:180017,180055)

详细信息

通讯作者: 张志远,E-mail:zzyent@126.com

中图分类号: R736.1

收稿日期: 2019-03-05

Evaluation of the role of melatonin in the metastasis of papillary thyroid carcinoma

- Department of Otolaryngology Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, 330006, China

More Information

Corresponding author: ZHANG Zhiyuan, E-mail: zzyent@126.com

Received Date: 05 March 2019

摘要

摘要: 目的:评估甲状腺乳头状癌患者中褪黑素(MT)水平及MT在甲状腺乳头状癌转移中的作用。方法:采用ELISA法检测81例甲状腺乳头状癌(PTC)患者和20例多结节性甲状腺肿(MNG)患者和20例健康成人血清MT水平,并分析其与PTC临床病理特征的关系;应用免疫组织化学检测81例甲状腺乳头状癌及癌旁组织中MT受体2个亚型MT1、MT2表达情况,并通过Image Pro Plusversion 6.0图像分析软件测量计算其平均光密度值(MOD)。结果:PTC患者的血清MT水平显著高于MNG患者和正常人(P<0.05);原发肿瘤T≥2 cm组MT水平显著高于T<2 cm组,颈部淋巴结阳性的患者(N≥1)的MT水平显著高于淋巴结阴性(N=0)(P<0.05)。MT1、MT2受体在PTC组织和癌旁组织中均有表达,主要定位于细胞膜和细胞质中,其中MT1受体在2组中呈低表达,差异无统计学意义;MT2受体在PTC组织中表达量显著高于癌旁组织(P<0.05),进一步分析显示,MT2受体在PTC组织中的表达量与颈部淋巴结转移相关,MT2受体在伴颈部淋巴结转移的PTC组织表达量显著低于无转移的(P<0.05)。结论:PTC患者血清MT水平较MNG和对照组高,可能与PTC呈低度恶性有关;MT可抑制PTC转移,其主要通过MT2受体发挥抗PTC转移作用。
- 甲状腺肿瘤 /
- MT /
- MT受体 /
- 淋巴转移
Abstract: Objective: To evaluate the level of melatonin and the role of melatonin in the metastasis of papillary thyroid carcinoma in patients with papillary thyroid carcinoma. Method: We measured serum melatonin levels in 81 patients with papillary thyroid carcinoma(PTC),20 patients with multinodular goiter(MNG) and 20 healthy adults using ELISA. The relationship between melatonin and clinicopathological features of PTC were analyzed.The expression of MT1 and MT2 in two subtypes of melatonin receptor in 81 cases of papillary thyroid carcinoma and adjacent tissues were detected by immunohistochemical SP method, and its the mean optical density(MOD) image was analyzed by Image Pro Plusversion(IPP) image processing software. Result: Serum melatonin concentration in patients with PTC was significantly higher than that in MNG patients and normal controls(P<0.05). The level of melatonin in the primary tumor T≥2 cm group was significantly higher than that in the T<2 cm group. Patients with positive cervical lymph nodes(N≥1) had significantly higher melatonin levels than lymph node negatives(N=0)(P<0.05). The MT1 and MT2 receptors were expressed in both PTC and paracancerous tissues, mainly in the cell membrane and cytoplasm. The expression of MT1 receptor was low in the two groups, and there was no statistical difference. The expression of MT2 receptor in PTC tissues Significantly higher than the adjacent tissues(P<0.05), further studies showed that the expression of MT2 receptor in PTC tissues was associated with cervical lymph node metastasis, and the expression of MT2 receptor in PTC tissues with cervical lymph node metastasis was significantly lower than that without metastasis(P<0.05).Conclusion: Serum melatonin levels in PTC patients were higher than those in MNG and control groups, which may be associated with low malignancy of PTC; melatonin inhibits PTC metastasis, which exerts anti-PTC metastasis mainly through MT2 receptors.
- papillary thyroid cancer /
- melatonin /
- melatonin receptor /
- lymphatic metastasis

HTML全文

参考文献(18)

[1]	KILFOY B A,ZHENG T,HOLFORD T R,et al.International patterns and trends in thyroid cancer incidence,1973-2002[J].Cancer Causes Control,2009,20:525-531.
[2]	CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015[J].Ca Cancer J Clin,2016,66:115-132.
[3]	REITER R J,ROSALES-CORRAL S A,TAN D X,et al.Melatonin,a Full Service Anti-Cancer Agent:Inhibition of Initiation,Progression and Metastasis[J].Int J Mol Sci,2017,18.pii:E843.
[4]	李岚,徐尔理,张征,等.MT与MT受体在成人甲状腺肿瘤中的表达及其意义[J].临床肿瘤学杂志,2007,12(11):843-846.
[5]	NIX P,NICOLAIDES A,COATESWORTH A P.Thyroid cancer review 1:presentation and investigation of thyroid cancer[J].Int J Clin Pract,2005,59:1340-1344.
[6]	ZOU Z W,LIU T,LI Y,et al.Melatonin suppresses thyroid cancer growth and overcomes radioresistance via inhibition of p65 phosphorylation and induction of ROS[J].Redox Biol,2018,16:226-236.
[7]	TALIB W H.Melatonin and Cancer Hallmarks[J].Molecules,2018,23:E518.
[8]	WRIGHT M L,CUTHBERT K L,DONOHUE M J,et al.Direct influence of melatonin on the thyroid and comparison with prolactin[J].J Exp Zool,2000,286:625-631.
[9]	ZASADA K,KARBOWNIK-LEWINSKA M.Comparison of potential protective effects of melatonin and propylthiouracil against lipidperoxidation caused by nitrobenzene in the thyroid gland[J].Toxicol Ind Health,2015,31:1195-1201.
[10]	CREIGHTON J A,RUDEEN P K.Effects of melatonin and thyroxine treatment on reproductive organs and thyroid hormone levels in male hamsters[J].JPineal Res,1989,6:317-323.
[11]	VRIEND J.Evidence for pineal gland modulation of the neuroendocrine-thyroid axis[J].Neuroendocrinology,1983,36:68-78.
[12]	BALTACI AK,MOGULKOC R.Leptin,neuropeptide Y(NPY),melatonin and zinc levels in experimental hypothyroidism and hyperthyroidism:relation with melatonin and the pineal gland[J].Horm Mol Biol Clin Investig,2018,34-34.
[13]	LEWI NSKI A,SEWERYNEK E.Melatonin inhibits the basal and TSH-stimulated mitotic activity of thyroid follicular cells in vivo and in organ culture[J].JPineal Res,1986,3:291-299.
[14]	MCLEOD D S,WATTERS K F,CARPENTER A D,et al.Thyrotropin and thyroid cancer diagnosis:a systematic review and dose-response meta-analysis[J].JClin Endocrinol Metab,2012,97:2682-2692.
[15]	REN W,LIU G,CHEN S,et al.Melatonin signaling in T cells:Functions and applications[J].J Pineal Res,2017,62-62.
[16]	LIU J,CLOUGH S J,HUTCHINSON A J,et al.MT1 and MT2 Melatonin Receptors:A Therapeutic Perspective[J].Annu Rev Pharmacol Toxicol,2016,56:361-383.
[17]	亢晓彬,马勇,魏伟.成人肝癌组织MT受体的表达和结合特性[J].中国药理学通报,2010,26(2):174-177.
[18]	LAI L,YUAN L,CHENG Q,et al.Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumorsand breast cancer cell lines[J].Breast Cancer Res Treat,2009,118:293-305.